Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
Authors:
Open Access
- 14 June 2023
- journal article
- research article
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 30 (1) , 1-12
Abstract
Background: Flavivirus causes many serious public health problems worldwide. However, licensed DENV vaccine has restrictions on its use, and there is currently no approved ZIKV vaccine. Development of a potent and safe flavivirus vaccine is urgently needed. As a previous study revealed the epitope, RCPTQGE, located on the bc loop in the E protein domain II of DENV, in this study, we rationally designed and synthesized a series of peptides based on the sequence of JEV epitope RCPTTGE and DENV/ZIKV epitope RCPTQGE. Methods: Immune sera were generated by immunization with the peptides which were synthesized by using five copies of RCPTTGE or RCPTQGE and named as JEV-NTE and DV/ZV-NTE. Immunogenicity and neutralizing abilities of JEV-NTE or DV/ZV-NTE-immune sera against flavivirus were evaluated by ELISA and neutralization tests, respectively. Protective efficacy in vivo were determined by passive transfer the immune sera into JEV-infected ICR or DENV- and ZIKV-challenged AG129 mice. In vitro and in vivo ADE assays were used to examine whether JEV-NTE or DV/ZV-NTE-immune sera would induce ADE. Results: Passive immunization with JEV-NTE-immunized sera or DV/ZV-NTE-immunized sera could increase the survival rate or prolong the survival time in JEV-challenged ICR mice and reduce the viremia levels significantly in DENV- or ZIKV-infected AG129 mice. Furthermore, neither JEV -NTE- nor DV/ZV-NTE-immune sera induced antibody-dependent enhancement (ADE) as compared with the control mAb 4G2 both in vitro and in vivo. Conclusions: We showed for the first time that novel bc loop epitope RCPTQGE located on the amino acids 73 to 79 of DENV/ZIKV E protein could elicit cross-neutralizing antibodies and reduced the viremia level in DENV- and ZIKV-challenged AG129 mice. Our results highlighted that the bc loop epitope could be a promising target for flavivirus vaccine development.Keywords
Funding Information
- Ministry of Science and Technology (MOST 109-2320-B-400-021, MOST 105-2628-B-016-002-MY2, MOST 109-2320-B-016-012)
- National Health Research Institutes (NHRI-110A1-MRCO-08212101)
- Ministry of National Defense Medical Affairs Bureau (MAB-110-104, MND-MAB-C04-111016)
This publication has 44 references indexed in Scilit:
- Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent EnhancementPLOS Neglected Tropical Diseases, 2013
- Partially Neutralizing Potency against Emerging Genotype I Virus among Children Received Formalin-Inactivated Japanese Encephalitis Virus VaccinePLOS Neglected Tropical Diseases, 2012
- Immune Response to Dengue Virus and Prospects for a VaccineAnnual Review of Immunology, 2011
- Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc ModificationPLOS Pathogens, 2010
- Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue DiseaseCell Host & Microbe, 2010
- Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomainsJournal of General Virology, 2009
- A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunityMicrobes and Infection, 2009
- Prospects for a dengue virus vaccineNature Reviews Microbiology, 2007
- Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus MonkeysJournal of Virology, 2005
- A highly attenuated strain of Japanese encephalitis virus induces a protective immune response in miceVirus Research, 1996